Several trials have also been performed with the monoclonal antibody atezolizumab which prevents the interaction of PD‐L1 with PD‐1 and B7.1 (CD80), which in turn causes less suppression of tumor‐reactive lymphocytes.32 Here, CD80 is linked to neoplasm.